Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441252 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
A Phase 2 study of Overweight or Obesity and Elevated Liver Fat, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 7
- Study locations
NCT07441252 is a Phase 2 study of Overweight or Obesity and Elevated Liver Fat that is actively recruiting participants, run by Amgen. The registered enrollment target is 180 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT07441252, a Phase 2 study of Overweight or Obesity and Elevated Liver Fat, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet and increased physical activity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maridebart cafraglutide
Study Locations (7)
Arizona
- Arizona Clinical Trials - Chandler
- Medical Advancement Centers of Arizona - Phoenix
Florida
- Indago Research and Health Center - Hialeah
- Floridian Clinical Research LLC - Miami Lakes
Maryland
- Woodholme Gastroenterology Associates - Glen Burnie - Glen Burnie
Nevada
- Excel Clinical Research - Las Vegas
Texas
- McAllen Research - Pharr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-03-05 |
| Est. Completion | 2027-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07441252
The ClinicalTrials.gov registry entry for NCT07441252 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Overweight or Obesity and Elevated Liver Fat appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07441252 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT07441252 about?
NCT07441252 is a clinical study titled "A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight". The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and body weight in participants living with obesity or overweight and elevated liver fat content, when administered in conjunction with reduced-calorie diet ...
What is the current status of trial NCT07441252?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-03-05. Estimated completion is 2027-12-22.
What conditions does trial NCT07441252 study?
This clinical trial studies the following conditions: Overweight or Obesity and Elevated Liver Fat.
What interventions are being tested in trial NCT07441252?
The interventions under investigation include: Placebo (DRUG), Maridebart cafraglutide (DRUG).
Who is sponsoring clinical trial NCT07441252?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07441252 being conducted?
This trial has 7 study locations across Arizona, Florida, Maryland, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.